KR20080080495A - 의학 영상용 짧은 아미노알코올 사슬과 금속착물을포함하는 화합물 - Google Patents

의학 영상용 짧은 아미노알코올 사슬과 금속착물을포함하는 화합물 Download PDF

Info

Publication number
KR20080080495A
KR20080080495A KR1020087010991A KR20087010991A KR20080080495A KR 20080080495 A KR20080080495 A KR 20080080495A KR 1020087010991 A KR1020087010991 A KR 1020087010991A KR 20087010991 A KR20087010991 A KR 20087010991A KR 20080080495 A KR20080080495 A KR 20080080495A
Authority
KR
South Korea
Prior art keywords
formula
group
choh
compound
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087010991A
Other languages
English (en)
Korean (ko)
Inventor
마르크 포트
Original Assignee
게르브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게르브 filed Critical 게르브
Publication of KR20080080495A publication Critical patent/KR20080080495A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020087010991A 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을포함하는 화합물 Ceased KR20080080495A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0510289 2005-10-07
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US73475605P 2005-11-09 2005-11-09
US60/734,756 2005-11-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009046A Division KR101440761B1 (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을 포함하는 화합물

Publications (1)

Publication Number Publication Date
KR20080080495A true KR20080080495A (ko) 2008-09-04

Family

ID=36636179

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087010991A Ceased KR20080080495A (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을포함하는 화합물
KR1020147009046A Active KR101440761B1 (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을 포함하는 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147009046A Active KR101440761B1 (ko) 2005-10-07 2006-10-09 의학 영상용 짧은 아미노알코올 사슬과 금속착물을 포함하는 화합물

Country Status (16)

Country Link
US (1) US8114863B2 (enExample)
EP (2) EP2457914B1 (enExample)
JP (2) JP5317270B2 (enExample)
KR (2) KR20080080495A (enExample)
CN (2) CN101305006B (enExample)
BE (1) BE2024C510I2 (enExample)
BR (1) BRPI0617151B8 (enExample)
CA (1) CA2625207C (enExample)
DK (1) DK1931673T3 (enExample)
ES (2) ES2519369T3 (enExample)
FI (1) FIC20240003I1 (enExample)
FR (2) FR2891830B1 (enExample)
NL (1) NL301259I2 (enExample)
PL (1) PL1931673T3 (enExample)
PT (1) PT1931673E (enExample)
WO (1) WO2007042506A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140052027A (ko) * 2011-08-17 2014-05-02 메르크 앤드 씨에 알부민-결합 개체들의 폴레이트 공액체들
KR20190098193A (ko) * 2016-12-21 2019-08-21 지이 헬스케어 에이에스 Mri 영상화제로서 적합한 테트라아자비시클로-매크로사이클 기재의 망가니즈 킬레이트 화합물
KR20210041566A (ko) * 2018-08-06 2021-04-15 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
KR20210109038A (ko) * 2019-01-17 2021-09-03 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta에서 유래된 킬레이트화 리간드의 착물 및 합성 방법
KR20210109039A (ko) * 2019-01-17 2021-09-03 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta로부터 유래된 킬레이트화 리간드의 착물, 및 제조 및 정제 공정
WO2024049087A1 (ko) * 2022-09-01 2024-03-07 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
KR20240031899A (ko) * 2022-09-01 2024-03-08 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
HRP20170874T4 (hr) * 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
WO2017098044A1 (en) * 2015-12-10 2017-06-15 Bracco Imaging Spa Dimeric contrast agents
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
WO2017178301A1 (en) * 2016-04-13 2017-10-19 Bracco Imaging Spa Contrast agents
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
US11110186B2 (en) 2017-12-20 2021-09-07 General Electric Company Anionic chelate compounds
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
HUE064567T2 (hu) 2020-07-16 2024-03-28 Guerbet Sa Eljárás 2-bróm-glutársav-diészterek elõállítására
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
CN116209661B (zh) 2020-07-17 2026-01-27 法国加栢 用于制备基于pcta的螯合配体的方法
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
WO2024215535A2 (en) * 2023-04-03 2024-10-17 Molecular Theranostics, Llc Extradomain b fibronectin targeting peptides and derivatives for cancer imaging and therapy
EP4464708A1 (en) 2023-05-17 2024-11-20 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
AU2024331870A1 (en) * 2023-09-01 2026-03-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Macrocyclic compound and use thereof
CN118791488B (zh) * 2024-09-14 2024-11-15 成都施贝康生物医药科技有限公司 化合物、螯合物及其在磁共振成像中的应用
CN118834263B (zh) * 2024-09-14 2024-12-03 成都施贝康生物医药科技有限公司 含短氨基醇链的化合物及其金属络合物和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag, 13353 Berlin 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
SG48889A1 (en) 1991-12-10 1998-05-18 Dow Chemical Co Bicycle-polyamacrocyclocarboxylic acid complexes conjugates preparation and use as contrast agents
ES2156143T3 (es) * 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
WO2001009188A1 (en) 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
WO2001052900A2 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Novel orthogonally protected amino acid chelators for biomedical applications
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
US20060155120A1 (en) 2003-05-23 2006-07-13 Amedio John C Optically pure and enriched isomers of chelating ligands and contrast agents
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
EP1699494A2 (en) 2003-11-24 2006-09-13 GE Healthcare AS Contrast agent imaging angiotensin ii receptors
EP1699466A4 (en) 2003-12-23 2009-03-11 Bracco Spa NEW CONNECTIONS AS METAL CHELATORS
CN101090739B (zh) 2004-07-02 2012-10-10 伯拉考成像股份公司 磁共振成像中用作高弛豫造影剂配体的1，4-二（羧甲基）氨基-6-甲基-全氢-1，4-二氮杂*（aazta)衍生物
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140052027A (ko) * 2011-08-17 2014-05-02 메르크 앤드 씨에 알부민-결합 개체들의 폴레이트 공액체들
KR20190098193A (ko) * 2016-12-21 2019-08-21 지이 헬스케어 에이에스 Mri 영상화제로서 적합한 테트라아자비시클로-매크로사이클 기재의 망가니즈 킬레이트 화합물
KR20210041566A (ko) * 2018-08-06 2021-04-15 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
KR20210109038A (ko) * 2019-01-17 2021-09-03 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta에서 유래된 킬레이트화 리간드의 착물 및 합성 방법
KR20210109039A (ko) * 2019-01-17 2021-09-03 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta로부터 유래된 킬레이트화 리간드의 착물, 및 제조 및 정제 공정
KR20210138134A (ko) * 2019-01-17 2021-11-18 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta로부터 유래된 킬레이트화 리간드의 착물, 및 제조 및 정제 공정
KR20210138133A (ko) * 2019-01-17 2021-11-18 게르브 가돌리늄과 부분입체이성질체적으로 풍부한 pcta에서 유래된 킬레이트화 리간드의 착물 및 합성 방법
WO2024049087A1 (ko) * 2022-09-01 2024-03-07 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
KR20240031899A (ko) * 2022-09-01 2024-03-08 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제

Also Published As

Publication number Publication date
FIC20240003I1 (fi) 2024-02-26
WO2007042506A1 (en) 2007-04-19
JP2009513574A (ja) 2009-04-02
FR24C1006I2 (fr) 2025-02-07
PL1931673T3 (pl) 2012-11-30
CN101305006B (zh) 2013-04-24
CA2625207A1 (en) 2007-04-19
ES2390092T3 (es) 2012-11-06
EP2457914A1 (en) 2012-05-30
NL301259I2 (nl) 2024-03-25
CN101305006A (zh) 2008-11-12
KR101440761B1 (ko) 2014-09-17
ES2519369T3 (es) 2014-11-06
FR2891830A1 (fr) 2007-04-13
CN103224495B (zh) 2015-07-15
EP2457914B1 (en) 2014-08-06
JP2013209400A (ja) 2013-10-10
CA2625207C (en) 2014-05-13
BRPI0617151B1 (pt) 2020-08-11
BRPI0617151A2 (pt) 2011-07-12
FR24C1006I1 (fr) 2024-04-19
DK1931673T3 (da) 2012-10-08
JP5731572B2 (ja) 2015-06-10
EP1931673B1 (en) 2012-08-29
KR20140060565A (ko) 2014-05-20
EP1931673A1 (en) 2008-06-18
US8114863B2 (en) 2012-02-14
FR2891830B1 (fr) 2011-06-24
BE2024C510I2 (enExample) 2026-01-14
JP5317270B2 (ja) 2013-10-16
PT1931673E (pt) 2012-09-24
US20090169479A1 (en) 2009-07-02
CN103224495A (zh) 2013-07-31
BRPI0617151B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
KR101440761B1 (ko) 의학 영상용 짧은 아미노알코올 사슬과 금속착물을 포함하는 화합물
US11401262B2 (en) Dimeric contrast agents
US7211241B2 (en) Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
US6440956B1 (en) Bicyclic polyaminoacid metal complexes, their process of preparation and their application in medical imaging
JP5368099B2 (ja) ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
US11007283B2 (en) Contrast agents
US10793533B2 (en) Dimeric contrast agents
US20020052354A1 (en) Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
HK1257515A1 (en) Dimeric contrast agents
HK1257515B (en) Dimeric contrast agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111007

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130531

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140305

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140129

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101001383

Request date: 20140305

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140404

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140305

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140305

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130830

Patent event code: PB09011R02I

E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20140502

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140305

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130830

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20140916

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2014101001383

Request date: 20140305

Appeal kind category: Appeal against decision to decline refusal